Abstract: The current consensus for the prevention and management of type 2 diabetes mellitus (T2DM) is that high-quality diets and adherence to a healthy lifestyle provide significant health benefits. Remarkably, however, there is little agreement on the proportions of macronutrients in the diet that should be recommended to people suffering from pre-diabetes or T2DM. We herein discuss emerging evidence that underscores the importance of gene-diet interactions in the improvement of glycemic biomarkers in T2DM. We propose that we can achieve better glycemic control in T2DM patients by coupling Mediterranean diets to genetic information as a predictor for optimal diet macronutrient composition in a personalized manner. We provide evidence to support this concept by presenting a case study of a T2DM patient who achieved rapid glycemic control when adhered to a personalized, genetically-guided Mediterranean Diet.

Keywords: type 2 diabetes mellitus; Mediterranean diet; SNP; nutrigenetics; personalized nutrition; glycemia

1. Introduction

Long considered a disease of minor significance, type 2 diabetes mellitus (T2DM) currently represents a major threat to human health with an estimated number of 425 million adult patients and four million deaths globally in 2017. Substantial evidence indicates that T2DM can be largely prevented or managed through adherence to a healthy lifestyle and a high-quality diet (as assessed by Healthy Eating Index-HEI [1]) is recommended to people at risk for diabetes or to T2DM patients as a therapy [2–5]. Surprisingly, however, there are no specific recommendations for the proportions of macronutrient intake that should be applied for people suffering from pre-diabetes or diabetes [6]. The Obesity Society, for example, recommends a diet comprising approximately 30% energy from total fat [15–20% from monounsaturated fatty acids (MUFA), 10% from polyunsaturated fatty acid (PUFA), 7% from saturated fatty acids (SFA)], 15–35% from protein and 45–65% energy from carbohydrates for the management of T2DM [7]. On the other hand, the Mediterranean diet (Med Diet) which demonstrates benefits over several metabolic diseases including T2DM, is considered a high fat diet (40% total fat) but rich in MUFA and poor in saturated fat [8–10]. Notably, the traditional Med Diet is rich in fibers and high-quality foods that have been proven a key strategy to achieve glycaemic control [11]. For example, grains, whole grain flours and breads from traditional Greek wheat varieties of Triticum monococcum and Triticum dicoccum, contain very high levels of alkylresorcinols [12] which have been associated with increased insulin sensitivity in metabolic syndrome patients [13] but are absent from white flour and its products.
It is therefore evident that there are no “golden rules” guiding the proportion of macronutrients for T2DM dietary therapy [14]. Moreover, even though the Med Diet has been proven successful in reducing chronic disease burden at population level [15], it does not take into account individualized needs and, as many other diets, it is based on population average. As a result, the search for an ideal high-quality diet for diabetes patients continues to grow.

In addition, T2DM is a highly heterogeneous disease influenced by genetic factors and nutrient-gene interactions, as indicated by twin and family studies [16–18]. With the emergence of genome wide association studies (GWAS) and more recently exome sequencing, a plethora of data has provided additional evidence for a genetic basis for T2DM. More than 140 genomic loci have been associated with predisposition to T2DM, improving our understanding of the genetic architecture and biology of the disease [19]. Genetics also influences individual responses to both macro- and micro-nutrients [20,21] and emerging evidence underscores the importance of gene–diet interactions in the improvement of glycaemic biomarkers.

We herein review the published evidence linking genetic variation to the selection of specific macronutrient composition for the management of T2DM (Table 1). Our overarching concept is to bridge the Med Diet with genetic information that can be used as predictor for optimal diet macronutrient composition in a personalized manner. We propose that by taking into account genetic information when formulating Med Diet-based nutritional recommendations, we can achieve better glycaemic control in T2DM patients. Herein we provide evidence to support this concept by presenting a case study of a T2DM patient who achieved rapid glycaemic control when adhered to a personalized, genetically-guided Med Diet.

Table 1. Gene variants associated with the selection of specific macronutrients for the dietary management of T2DM.

| Gene                                         | Variants                              | Macronutrient/s Involved in Health Outcome | Health Outcome Related to T2D                                                                 | Cohort/Time                                                                 | Reference |
|-----------------------------------------------|---------------------------------------|------------------------------------------|---------------------------------------------------------------------------------------------|-------------------------------------------------------------------------------|-----------|
| **Carbohydrates (CHO)**                       |                                       |                                          |                                                                                             |                                                                               |           |
| *MTNR1B* Melatonin receptor 1B                | rs1387153 (C/T)                       | T risk allele for T2D; C is the common allele | Increment of 1% of CHO                                                                      | 0.003 mmol/L higher fasting glucose with each additional 1% carbohydrate intake in the presence of the *MTNR1B* rs1387153 risk T allele | 5 cohort studies including up to 28,190 participants of European descent from the Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium. [22] |
| *APOA5* Apolipoprotein A5                     | rs662799 (T/C)                        | C risk allele dyslipidemias; T is the common allele | Substitution of high-quality CHO with low quality (whole grains and legumes substitution with refined rice) | Patients with impaired glucose carrying the *APOA5* rs662799 risk allele C showed a greater increase in the mean percent changes of triglyceride and apolipoprotein A5 when they substituted whole grains and legumes with refined rice | 93 patients with impaired glucose with 50 risk allele carriers/12 weeks [23] |
| Gene | Variants | Macronutrient/s Involved in Health Outcome | Health Outcome Related to T2D | Cohort/Time | Reference |
|------|----------|------------------------------------------|-------------------------------|-------------|-----------|
| CRY1 (Cryptochrome Circadian Regulator 1) | rs2287161 (G/C minus) C risk allele for mood disorders; G is the common allele | Increase in CHO intake (% of energy intake) | Two independent populations: a Mediterranean (n = 728) and a European origin North American population (n = 820). | [24] |
| PCSK7 (Proprotein convertase subtilisin/kexin type 7) | rs236918 (C/G minus) G risk allele (rare) for increased levels of ferritin and soluble transferrin receptor (sTfR) and liver cirrhosis; C is the common allele | High CHO (55–65%) vs low CHO (35–45%) of low glycemic index | 730 overweight or obese adults 2-year weight-loss trial | [25] |
| TCF7L2 Transcription Factor 7-Like 2 | rs7903146 (C/T) T risk allele for T2D; C is the common allele | High-quality CHO | Cohort of 24,799 non-diabetic individuals from the Malmö Diet and Cancer Study (MDCS), with dietary data obtained by a modified diet history method, follow up for 12 years, with 1,649 recordings of incident T2D made | [26] |
| GCKR Glucokinase regulatory protein | rs780094 (G/A minus) A risk allele for T2D and dyslipidemias; G is the common allele | High-quality CHO | 14 cohorts comprising ~48,000 participants of European descent (meta-analysis) | [27] |
| PPM1K PP2C domain-containing protein phosphatase 1K | rs1440581 (C/T minus) C risk allele. For T2D and increased BCAA/AAA ratio; T is the common allele | Low-fat diet (20% fat) vs high-fat diet (40% fat) | 734 overweight or obese adults 2-year weight-loss trial | [28] |
### Table 1. Cont.

| Gene | Variants | Macronutrient/s Involved in Health Outcome | Health Outcome Related to T2D | Cohort/Time | Reference |
|------|----------|------------------------------------------|-----------------------------|-------------|-----------|
| **PPM1K** PP2C domain-containing protein phosphatase 1K | rs1440581 (C/T minus) C risk allele. For T2D and increased BCAA / AAA ratio; T is the common allele | Low-fat diet: 20–25% fat, 15% protein, and 60–65% carbohydrate; high-fat diet: 40–45% fat, 15% protein, and 40–45% carbohydrate | In high-fat diet, the T allele was associated with a higher reduction of insulin and HOMA-B. # The opposite effect was observed in the low-fat diet group, although in this group the T allele was marginally associated with insulin and HOMA-B, | 757 nondiabetic individuals who were randomly assigned to 1 of 2 energy-restricted diets that differed in macronutrient composition | [29] |
| Genetic score of SNPs related to habitual coffee consumption | 8 SNP | Low-fat diet (20% fat) and high-fat diet (40% fat) | Participants genetically prone to high coffee consumption may benefit more by eating a low-fat diet in improving fasting insulin and HOMA-IR in a short term (Actual coffee consumption was not taken into account) | 811 overweight or obese individuals aged 30–70 y and with a BMI (in kg/m²) of 25–40. 2-year weight-loss trial | [30] |
| **CLOCK** Clock circadian regulator | rs4580704 (G/T) G allele with protective effect for T2D; C is the common allele | MUFA > 13.2% of energy SFA intakes (>11.8%). | The protective effect of the CLOCK rs4580704 G allele on insulin sensitivity was only present when MUFA intake was >13.2% of energy. The adverse effect of C allele variant on waist circumference was only observed with high saturated fatty acid intakes (>11.8%). | Participants (n = 1100) in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) | [31] |
| **CLOCK** Clock circadian regulator | rs1801260 (C/T) C risk allele for MetS; T is the common allele | High saturated fatty acid (SFA) intakes (>11.8%). | Individuals carrying the CLOCK rs1801260 risk C allele had increased waist circumference only with high saturated fatty acid intakes (>11.8%). | Participants (n = 1100) in the Genetics of Lipid Lowering Drugs and Diet Network (GOLDN) | [31] |
| Genetic risk score (GRS) SNPs related for fasting glucose | 14 SNPs | Low-fat diet (20% fat) and high-fat diet (40% fat) | Participants with a higher genetic risk may benefit more by eating a low-fat diet to improve glucose metabolism. | 733 adults 2-year weight-loss trial | [32] |
| **CLOCK** Clock circadian regulator | rs1801260 (C/T) C risk allele for MetS; T is the common allele | Med Diet: 35% fat, 22% monounsaturated fatty acids (MUFA) versus low-fat diet (28% fat, 12% MUFA). | 12 months of low-fat intervention, subjects who were homozygous for the common allele T displayed lower plasma insulin concentrations lower insulin resistance and higher insulin sensitivity compared with carriers of CLOCK rs1801260 risk allele C (TC + CC). The opposite effect observed with MedDiet although didn’t reach statistical significance | 5 MetS subjects participating in the CORDIOPREV 12 month intervention | [33] |
| Gene                        | Variants                        | Macronutrient/s Involved in Health Outcome | Health Outcome Related to T2D                                                                 | Cohort/Time                        | Reference |
|-----------------------------|---------------------------------|-------------------------------------------|------------------------------------------------------------------------------------------------|------------------------------------|-----------|
| ADIPOQ Adiponectin          | rs266729 (C/G)                  | C risk allele for increased waist circumference; G allele protective effect against colon cancer | A reduction in plasma SFAs lowers insulin resistance in MetS subjects who are ADIPOQ rs266729 CC carriers and ADIPOR1 rs10920533 AA carriers | 451 subjects with the MetS who participated in the LIPGENE | [34]      |
| ADIPOR1 Adiponectin receptor 1 | rs10920533 (G/A)             | A risk allele for increased waist circumference; A is the common allele |                                           |                                    |           |
| CLOCK clock circadian regulator | rs4580704 (G/C)               | G allele with protective effect for T2D; C is the common allele | Med Diet increased the protective effects of the CLOCK rs4580704 G-allele against T2D and stroke | 7098 PREDIMED trial (ISRCTN35739639) participants after a median 4.8-year follow-up. | [35]      |
| TCF7L2 Transcription Factor 7-Like 2 | rs7903146 (C/T)            | T risk allele for T2D; C is the common allele | High dietary SFA intake (≥15.5% energy) exacerbated MetS risk and was associated with further impaired insulin sensitivity in the T allele carriers relative to the CC homozygotes and particularly to the T allele carriers with the lowest SFA intake | LIPGENE-SU.VI.MAX study of MetS cases and matched controls (n = 1754) Cohort of 13,000 individuals studied over 7.5 years beginning in 1994 to 2002 | [36]      |
| LEPR Leptin receptor        | rs3790433 (G/A minus)          | G risk allele (common) for insulin resistance; A is rare allele | Individuals with LEPR rs3790433 GG genotype exacerbated their risk to hyperinsulinemia and insulin resistance when their plasma levels where low for (n-3) and high for (n-6) PUFA These associations were abolished against a high (n-3) or low (n-6) PUFA background. | LIPGENE-SU.VI.MAX study of MetS cases and matched controls (n = 1754). Cohort of 13,000 individuals studied over 7.5 years beginning in 1994 to 2002 | [37]      |
| Low-protein related to diabetes | Low-protein diet (15% protein) and high-protein diets (25% protein). | Low plasma (n-3) and high (n-6) PUFA | Individuals with a lower genetic risk of diabetes may benefit more from consuming a low-protein weight-loss diet in improving insulin resistance and β cell function, whereas a high-protein diet may be more beneficial for white patients with a higher genetic risk | 744 overweight or obese nondiabetic adults 2-year weight-loss trial Pounds lost trial | [38]      |
| Gene | Variants | Macronutrient/s Involved in Health Outcome | Health Outcome Related to T2D | Cohort/Time | Reference |
|------|----------|------------------------------------------|-----------------------------|-------------|-----------|
| GRS related to BMI and/or WHR | 159 SNPs SNPs related to obesity abdominal obesity and T2D | Low-protein diet (15% protein) and high-protein diets (25% protein). | Participants with higher WHR only*+PGS showed less increased fasting glucose and less reduction in HOMA-B when consuming an average-protein diet, compared with lower WHR only+PGS. Conversely, eating high-protein diet was associated with less decreased HOMA-B among individuals with lower than higher WHR only+PGS *waist-hip ratio-increase only | 692 overweight participants (84% white Americans) 2-year weight-loss trial Pounds lost trial | [39] |
| DHC7 7- Dehydrocholesterol Reductase | rs12785878 (T/G) T risk allele for vitamin D deficiency G allele rare in Caucasians (no health effect) | Low-protein diet (15% protein) and high-protein diets (25% protein). | Individuals carrying the DHC7 rs12785878 T genotype might benefit more in improvement of insulin resistance than noncarriers by consuming high-protein weight-loss diets. | 6 months (up to 656 participants) and 2 years (up to 596 participants) 6 and 2-year weight-loss trial Pounds lost trial | [40] |
| S100 Calcium-binding protein A9 (S100A9) | rs3014866 (C/T) C risk allele for T2D T allele protective against diabetes. | Low SFA: CHO ratio | Individuals with the S100A9 rs3014866 CC risk genotype may be more likely to benefit from a low SFA: carbohydrate ratio intake to improve insulin resistance as evaluated with the use of the HOMA-IR | 3 diverse populations: the CORDIOPREV (Coronary Diet Intervention with Olive Oil and Cardiovascular Prevention; n = 711), which consisted of Spanish white adults; the GOLDN (Genetics of Lipids Lowering Drugs and Diet Network; n = 818), which involved North American non-Hispanic white adults; and Hispanic adults who participated in the BPRHS (Boston Puerto Rican Health Study; n = 1155). | [41] |
| GIPR Gastric inhibitory polypeptide receptor | rs2287019 (C/T) C risk allele for T2D T allele rare | Low-fat diet (20% fat) and high-fat diet (40% fat) High CHO (55–65%) vs low CHO (35–45%) of low glycemic index | The T allele of GIPR rs2287019 is associated with greater improvement of glucose homeostasis in individuals who choose a low-fat, high-carbohydrate, and high-fiber diet. | 737 overweight adults 2-year weight-loss trial Pounds lost trial | [42] |

**MIXED DIETARY PATTERNS**

3 diverse populations: the CORDIOPREV (Coronary Diet Intervention with Olive Oil and Cardiovascular Prevention; n = 711), which consisted of Spanish white adults; the GOLDN (Genetics of Lipids Lowering Drugs and Diet Network; n = 818), which involved North American non-Hispanic white adults; and Hispanic adults who participated in the BPRHS (Boston Puerto Rican Health Study; n = 1155).
### Table 1. Cont.

| Gene                  | Variants                  | Macronutrient/s Involved in Health Outcome | Health Outcome Related to T2D                                                                 | Cohort/Time                          | Reference |
|-----------------------|---------------------------|------------------------------------------|----------------------------------------------------------------------------------------------|--------------------------------------|-----------|
| IRS1 Insulin receptor substrate 1 | rs2943641 (C/T) C risk allele for T2D; T allele rare | Low-fat diet (20% fat) and high-fat diet (40% fat) High CHO (55–65%) vs low CHO (35–45%) of low glycemic index | Individuals with the IRS1 rs2943641 CC genotype obtain more benefits in weight loss and improvement of insulin resistance than those without this genotype by choosing a high-carbohydrate and low-fat diet | 738 overweight adults 2-year weight-loss trial Pounds lost trial | [43]       |
| PLIN-1 Perilipin 1    | rs894160 (G/A minus) A risk allele for increased waist circumference and T2D; G is the common allele | SFA: CHO | | | |
| GRS for T2D           | 10 SNPs                   | Protein, SFA low quality food              | Intakes of processed meat, red meat, and heme iron (Western dietary pattern) showed significant interactions with GRS in relation to diabetes risk. The diet-diabetes associations were more evident among men with a high GRS than in those with a low GRS. | Health Professionals Follow-Up Study (HPFS) cohort (prospective) Nested, case-control study of 1196 diabetic and 1337 nondiabetic men. 1986–2000 | [45]       |
| TCF7L2 Transcription Factor 7-Like 2 | rs7903146 (C/T) T risk allele for T2D; C is the common allele | High intake of desserts and milk | The T2D risk was greater in T allele carriers with high dessert and milk. In subjects with a high dessert intake, the T allele was also associated with higher fasting plasma glucose concentrations | 787 subjects (378 men and 409 women, aged between 30 and 64). | [46]       |

### 2. Genetic Variations Guiding Carbohydrate Intake in T2DM

#### 2.1. Genetic Variants Guiding the Quantity of Carbohydrate Intake

Even though carbohydrates (CHO) have a major dietary influence on postprandial blood glucose, evidence on total carbohydrate needs and T2DM is largely conflicting [26]. Surprisingly, even the anticipated protective effect of total fruit intake on T2DM could not be replicated in a meta-analysis contacted in the context of the European Prospective Investigation into Cancer (EPIC)-InterAct study [47]. Genetic variation is likely to account for the heterogeneity of T2DM patient responses to carbohydrates (Table 1). Indeed, several polymorphisms have recently been identified to influence glucose levels in response to...
carbohydrate intake. Among them, transcription factor 7-like 2 (TCF7L2) gene variant rs7903146 has attracted significant attention as it is one of the strongest genetic markers of predisposition to diabetes, with the TT genotype increasing disease risk by 40–50% [48]. Interestingly, even though this high risk polymorphism is associated with lower BMI ([49] and our unpublished data on Greek population), it is also associated with significantly higher increase of fasting glucose when consuming increased amounts of desserts compared to non-carriers [46].

The melatonin receptor 1b (MTNR1B) variant rs1387153 is another example of genetic variation influencing T2DM patient responses to CHO. An analysis of 5 cohort studies including more than 28,000 participants has demonstrated that the minor T allele of rs1387153 strongly interacts with CHO in modulating fasting glucose, to the extent that every 1% increase in CHO intake exacerbates the fasting glucose-raising effect of the T allele [22].

Cryptochrome 1 (CRY1) variant rs2287161, which has been associated with the regulation of circadian rhythms and linked to depression and sleep disturbance [50], also modifies the CHO effect on glycaemic indices. In this case, increased carbohydrate intake (as a percentage of energy intake) was associated with elevated HOMA-IR and fasting insulin only among individuals homozygous for the risk allele C [24]. In contrast, G homozygotes for pro-protein convertase subtilisin/kexin type 7 (PCSK7) gene variant rs236918 who were assigned to a high-carbohydrate diet displayed a greater decrease in fasting insulin levels and HOMA-IR than non-carriers [25]. Interestingly, both MTNR1B and PCSK7 polymorphisms have been associated with increased risk of diabetes [51,52].

2.2. Genetic Variants Guiding the Quality of Carbohydrate Intake

The quality of carbohydrates appears to play important roles in the management of T2DM and the results of relevant prospective studies and clinical trials are much more coherent compared to those addressing the impact of the quantity of carbohydrates on T2DM [53]. People with diabetes and those at risk for diabetes are encouraged to consume at least the amount and quality of dietary fibre recommended for the general public that includes vegetables, pulses and fruit [54].

However, emerging evidence suggests that genetic variation may influence individual responses to different sources of fibre. Among them, TCF7L2 gene variant rs7903146 has attracted significant attention [48]. Interestingly, two independent studies have reported that whole grain as a dietary source of CHO is associated with protection from T2DM only among non-risk CC genotype carriers [26,55]. This suggests that carriers of a T allele of rs7903146 would not benefit from a whole grain-enriched diet and alternative dietary approaches should be explored.

Likewise, the glucokinase regulatory protein (GCKR) gene variant rs780094, which has been explored as a component of polygenic risk for T2DM and dyslipidemia [56] diminishes the beneficial effects of whole-grain foods on insulin homeostasis, possibly via the reported effect of GCKR variant on both triglyceride and glucose levels [27].

Another gene polymorphism associated with the response of T2DM patients to particular sources of carbohydrates is apolipoprotein-A5 (APOA5) SNP rs964184. It has been reported that compared to rs964184 TT homozygotes, T2DM patients with impaired fasting glucose who carry the C allele of rs964184 could be more susceptible to the adverse effects of a high carbohydrate diet based on refined rice by having an elevation of triglycerides [23]. Therefore, the replacement of refined rice with whole grains and legumes in a high carbohydrate diet should be considered for individuals with impaired fasting glycemia who carry the APOA5 rs964184 C variant, to prevent diabetic hypertriglyceridemia.

3. Genetic Variations Guiding Fat Intake in T2DM

Even though fat consumption has broadly been associated with elevated risk for the development of metabolic diseases, there is still a debate about the recommended daily intake of fat in T2DM patients, reportedly ranging from 10% up to 40% [14]. Conflicting
data may be due to variations in food sources of fat [57] or the proportion of fat in the context of the overall dietary pattern. Indeed, according to the PREDIMED clinical study, individuals who adhered to a Med Diet plan supplemented with extra virgin olive oil had on average 40% lower risk to develop diabetes compared to those following a low-fat diet [58].

Several genes have been identified to impact responses to fat in T2DM. One of them is PPM1K (phosphatase, Mg^{2+}/Mn^{2+}-dependent 1 K) gene variant rs1440581. Individuals who are homozygous for the T allele of this SNP benefit most by a high-fat diet (40–45% fat, 15% protein, and 40–45% carbohydrate) in reducing insulin and homeostatic model assessment for β-cell function (HOMA-B) during weight loss whereas the opposite effect is observed for a low fat diet (20–25% fat, 15% protein, and 60–65% carbohydrate) [29]. Similarly, in another intervention study, the C allele was related to smaller decreases in serum insulin and homeostatic model assessment for insulin resistance (HOMA-IR) in obese and overweight individuals following an energy-restricted high-fat diet plan (40% energy intake from fat), whereas an opposite genotype effect on changes in insulin and HOMA-IR was observed in a low-fat diet group (20% energy intake from fat [28]). Together, these reports suggest that pro-diabetes or T2DM patients with PPM1K rs1440581 TT genotype would benefit from an energy-restricted high-fat diet whereas carriers of the C allele could be advised to follow a low-fat diet.

Genetic risk scores (GRS), generated by combining the additive effects of several genetic variants, have also been explored to predict optimal dietary fat composition for T2DM patients. For example, a high genetic risk score (GRS) of 14 fasting glucose-associated SNPs could predict health benefit for a diet low in fat [32]. Furthermore, in another study [30] a significant interaction between a genetic score calculated on the basis of eight variants previously associated with habitual coffee consumption [59] and dietary fat intake was observed. It was shown that the group with the highest genetic score for coffee consumption had significantly greater reduction in fasting insulin when following a low fat diet. Interestingly, even though the initial idea of this study was based on the fact that coffee consumption is associated with improved insulin sensitivity and reduced risk for diabetes [60], actual coffee consumption was not considered [30].

Variations in food sources of fat may play an important role in modulating fasting glucose and other bioclinical variables in T2DM patients. In general, replacing saturated with unsaturated fat in the diet reduces total cholesterol, LDL-C and CVD risk [61]. Surprisingly, a meta-analysis of observational studies has not identified high dietary saturated fatty acid (SFA) intake as a risk factor for T2DM [62]. However, this conclusion should be considered through the prism of genetic variation. Indeed, high dietary SFA intake (>15.5% energy) impairs insulin sensitivity and increases the risk for metabolic syndrome in carriers of the T risk allele of TCF7L2 rs7903146 polymorphism relative to CC homozygotes [36]. Likewise, high dietary SFA intake (>11.8% energy) leads to increased waist circumference and consequently increases the risk for metabolic syndrome in carriers of the C risk allele of CLOCK rs1801260 [31]. Furthermore, diets rich in MUFA and PUFA may have a dual role as they can either reveal the protective effect that some polymorphisms have towards T2DM [35] or to abolish the detrimental effects of some others [34].

4. Genetic Variations Guiding Protein Intake in T2DM

Typically, the average daily level of protein intake for people with diabetes is 1–1.5 g/kg body weight/day or 15–20% of total calories. However, two published meta-analyses have indicated that high protein diets confer several health benefits in diabetes patients [63,64].

We reason that genetic variation may affect individual responses to different protein percentages in the diet (Table 1). Several studies support this notion. For example, polygenic scores, based on combinations of multiple susceptibility loci identified by GWAS, are increasing explored because they reflect the polygenic nature of T2DM and are more relevant to gene–diet interactions. A recent study demonstrated interaction between a polygenic score of 31 T2DM risk alleles and protein percentage in the diet. In particular,
individuals with a lower polygenic score for T2DM showed more favourable responses to low-protein diets, including greater decreases in fasting insulin, HbA1c, and homeostatic model assessment for insulin resistance (HOMA-IR), and a lesser increase in and homeostatic model assessment for β-cell (HOMA-B) function, than did individuals with a higher risk score within 2 years of follow-up [38]. Another study similarly explored 159 obesity genes combined with phenotypic characteristics such as waist hip ratio and BMI to create different adiposity subtypes which were found to differentially modify the effect of protein intake on improving glucose metabolism [39].

An interaction between vitamin D metabolism-related variants and macronutrient responses in the context of T2DM was demonstrated by the Pounds Lost Trial group; patients with the vitamin D-increasing T allele of the DHCR7 variant rs12785878 had a greater improvement of glycaemic parameters when assigned to high-protein diets, whereas improvement was not evident in those who followed a low protein diet [40].

5. Genetic Variations and Mixed Dietary Patterns for the Management of T2DM

A variety of dietary patterns are acceptable for the management of diabetes. Still, the evidence surrounding comparative benefits of different macronutrient ratios or dietary patterns in T2DM patients and the influence of genetics thereof is scarce [14].

One example of genetic variation influencing responses to mixed dietary patterns is GIPR variant rs2287019 (Table 1). T2DM patients who carry the T allele of rs2287019 and choose a low-fat, high-carbohydrate and high-fibre diet, show greater improvement in glucose homeostasis [42]. Likewise, it has been reported that T2DM patients carrying the IRS1 variant rs2943641 CC genotype might obtain more benefits in weight loss and improvement of insulin resistance than those without this genotype when they adhere to a high-carbohydrate and low-fat diet [43]. Additionally, T2DM patients who are homozygous for the C allele of S100A9 (S100 calcium-binding protein A9) rs3014866 variant are more likely to benefit from a low SFA:carbohydrate ratio intake to improve insulin sensitivity, based on HOMA-IR levels [41]. A western type diet, characterised by high intake of processed meat, red meat and heme iron, increases the risk of T2DM in individuals with a high polygenic score defined by ten T2DM risk alleles [45].

6. Discussion

Rapidly evolving technologies have offered unparalleled opportunities to assess bioclinical, dietary and genetic data that can improve the management of metabolic diseases such as T2DM. As indicated in this review, high-quality diets rich in n-3 PUFA and MUFA and low in saturated fat are universally proposed for the prevention and management of T2DM. This concept aligns with the Mediterranean dietary patterns typified by high-quality nutritional elements offering several health benefits. Notably, there is significant variation in the macronutrient distribution among different Mediterranean diets (Cretan/Greek, Italian, Spanish or Mediterranean-like) [65]. Likewise, dietary recommendations for T2DM patients largely vary with respect to macronutrient distribution which may impair the efficacy and goals of nutritional therapy for diabetes [14].

We propose that prevention and management of T2DM could be improved by combining genetically-guided quantitative and qualitative macronutrient recommendations (Table 1) with the high quality nutrition patterns of Med Diets. We have successfully applied this concept to several T2DM patients. As an example, a normal weight male T2DM patient, homozygous for MTNR1B rs1387153 risk allele T, with a high genetic risk score for diabetes and a high genetic score for coffee consumption was advised to change the macronutrient distribution of his diet from 54% carbohydrate, 32% fat and 16% protein to lower carbohydrate (50%), low fat (25%) and high protein (25%) diet based on Mediterranean high quality foods and olive oil (rich in MUFA and low in saturated fat) [66–68]. Some life style changes were also recommended based on his genetic makeup, such as not to consume dinner late at night and breakfast early in the morning and to avoid early rising (this individual was homozygous to MTNR1B rs10830963 risk allele G which is in linkage disequilibrium with rs1387153 in Greek
people) [69–71]. Two months later he had significantly lower plasma insulin concentrations and higher insulin sensitivity.

The emerging prospects of precision nutrition call for re-evaluation of dietary therapies for T2DM taking into account genetic information that could enable stratification of patients towards specific macronutrient intakes. Intervention and observational studies should involve collection of extensive dietary exposure data and, importantly, validation in independent populations to provide solid evidence for interactions between genotype, diet and disease [72].

**Author Contributions:** Conceptualization, K.G. and A.G.E.; methodology and data curation, K.G., E.L. and E.S.; writing—original draft preparation, K.G. and A.G.E.; writing—review and editing, all authors. All authors have read and agreed to the published version of the manuscript.

**Funding:** This research received no external funding.

**Institutional Review Board Statement:** Not applicable.

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Non applicable.

**Conflicts of Interest:** The authors declare no conflict of interest with the exception of K.G. who is founder and CEO of Embodiagnostics S.A.

**References**

1. Guenther, P.M.; Reedy, J.; Krebs-Smith, S.M. Development of the Healthy Eating Index-2005. *J. Am. Diet. Assoc.* 2008, 108, 1896–1901. [CrossRef] [PubMed]
2. Hu, F.B.; Manson, J.E.; Stampfer, M.J.; Colditz, G.A.; Liu, S.; Solomon, C.G.; Willett, W.C. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. *N. Engl. J. Med.* 2001, 345, 790–797. [CrossRef] [PubMed]
3. Mangou, A.; Grammatikopoulou, M.G.; Mirkopoulou, D.; Sailer, N.; Kotzamanidis, C.; Tsigga, M. Associations between diet quality, health status and diabetic complications in patients with type 2 diabetes and comorbid obesity. *Endocrinol. Nutr.* 2012, 59, 109–116. [CrossRef] [PubMed]
4. Buse, J.B.; Wexler, D.J.; Tsapas, A.; Rossing, P.; Mingrone, G.; Mathieu, C.; D’Alessio, D.A.; Davies, M.J. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care* 2020, 43, 487–493. [CrossRef] [PubMed]
5. Baltzis, D.; Grammatikopoulou, M.G.; Papanas, N.; Trakatelli, C.M.; Kotzamanidis, C.; Tsigga, M. Associations between diet quality, health status and diabetic complications in patients with type 2 diabetes and comorbid obesity. *Endocrinol. Nutr.* 2012, 59, 109–116. [CrossRef] [PubMed]
6. Buitrago, H.; Hu, F.B.; Manson, J.E.; Stampfer, M.J.; Colditz, G.A.; Liu, S.; Solomon, C.G.; Willett, W.C. Diet, lifestyle, and the risk of type 2 diabetes mellitus in women. *N. Engl. J. Med.* 2001, 345, 790–797. [CrossRef] [PubMed]
7. Gonzalez-Campoy, J.M.; St Jeor, S.T.; Castorino, K.; Ebrahim, A.; Hurley, D.; Jovanovic, L.; Mechanick, J.I.; Petak, S.M.; Yu, Y.H.; Harris, K.A.; et al. Clinical practice guidelines for healthy eating for the prevention and treatment of metabolic and endocrine diseases in adults: Cosponsored by the American Association of Clinical Endocrinologists/the American College of Endocrinology and the Obesity Society. *Endocr. Pract.* 2013, 19 (Suppl. 3), 1–82. [CrossRef]
8. Huo, R.; Du, T.; Xu, Y.; Xu, W.; Chen, X.; Sun, K.; Yu, X. Effects of Mediterranean-style diet on glycemic control, weight loss and cardiovascular risk factors among type 2 diabetes individuals: A meta-analysis. *Eur. J. Clin. Nutr.* 2015, 69, 1200–1208. [CrossRef]
9. Ferro-Luzzi, A.; James, W.P.; Kafatos, A. The high-fat Greek diet: A recipe for all? *Eur. J. Clin. Nutr.* 2002, 56, 796–809. [CrossRef]
10. Willett, W.C.; Sacks, F.; Trichopoulou, A.; Drescher, G.; Ferro-Luzzi, A.; Helsing, E.; Trichopoulous, D. Mediterranean diet pyramid: A cultural model for healthy eating. *Am. J. Clin. Nutr.* 1995, 61, 1402S–1406S. [CrossRef]
11. Georgoulis, M.; Kontogianni, M.D.; Yiannakouris, N. Mediterranean diet and diabetes: Prevention and treatment. *Nutrients* 2014, 6, 1406–1423. [CrossRef]
12. Psaltopoulou, T.; Katsouyanni, K.; Trichopoulou, A.; Jovanovic, L.; Mechanick, J.I.; Trichopoulous, D.; Kostaniotis, K.; et al. Mediterranean diet reduces plasma insulin concentrations and increases insulin sensitivity in type 2 diabetes mellitus patients: A randomized study. *Eur. J. Clin. Nutr.* 2015, 69, 1200–1208. [CrossRef]
13. Magnusdottir, O.K.; Landberg, R.; Gunnarsdottir, I.; Cloetens, L.; Akesson, B.; Landin-Olsson, M.; Rosqvist, E.; Iggman, D.; Schwab, U.; Herzig, K.H.; et al. Plasma alkylresorcinols C17:0/C21:0 ratio, a biomarker of relative whole-grain rye intake, is associated to insulin sensitivity: A randomized study. *Eur. J. Clin. Nutr.* 2014, 68, 453–458. [CrossRef] [PubMed]
14. Evert, A.B.; Dennis, M.; Gardner, C.D.; Garvey, W.T.; Lau, K.H.K.; MacLeod, J.; Mitri, J.; Pereira, R.F.; Rawlings, K.; Robinson, S.; et al. Nutrition Therapy for Adults with Diabetes or Prediabetes: A Consensus Report. *Diabetes Care* 2019, 42, 731–754. [CrossRef] [PubMed]
15. Martinez-Gonzalez, M.A.; de la Fuente-Arrillaga, C.; Nunez-Cordoba, J.M.; Basterra-Gortari, F.J.; Beunza, J.J.; Vazquez, Z.; Benito, S.; Tortosa, A.; Bes-Rastrollo, M. Adherence to Mediterranean diet and risk of developing diabetes: Prospective cohort study. *BMJ* 2008, 336, 1348–1351. [CrossRef] [PubMed]

16. Kaprio, J.; Tuomilehto, J.; Koskenvuo, M.; Romanov, K.; Reunanen, A.; Eriksson, J.; Stengard, J.; Kesaniemi, Y.A. Concordance for type 1 (insulin-dependent) and type 2 (non-insulin-dependent) diabetes mellitus in a population-based cohort of twins in Finland. *Diabetologia* 1992, 35, 1060–1067. [CrossRef]

17. Medici, F.; Hawa, M.; Janari, A.; Pyke, D.A.; Leslie, R.D. Concordance rate for type II diabetes mellitus in monozygotic twins: Actuarial analysis. *Diabetologia* 1999, 42, 146–150. [CrossRef]

18. Moore, A.F.; Florez, J.C. Genetic susceptibility to type 2 diabetes and implications for antidiabetic therapy. *Annu. Rev. Med.* 2008, 59, 95–111. [CrossRef]

19. Xue, A.; Wu, Y.; Zhu, Z.; Zhang, F.; Kemper, K.E.; Zheng, Z.; Yengo, L.; Lloyd-Jones, L.R.; Sidorenko, J.; Wu, Y.; et al. Genome-wide association analyses identify 143 risk variants and putative regulatory mechanisms for type 2 diabetes. *Nat. Commun.* 2018, 9, 2941. [CrossRef]

20. Gkouskou, K.K.; Vlastos, I.; Karkaloukos, P.; Chaniotis, D.; Sanoudou, D.; Eliopoulos, A.G. The “Virtual Digital Twins” Concept in Precision Nutrition. *Adv. Nutr.* 2020, 11, 1405–1413. [CrossRef]

21. Gkouskou, K.K.; Grammatikopoulou, M.G.; Vlastos, I.; Sanoudou, D.; Eliopoulos, A.G. Genotype-guided dietary supplementation in Precision Nutrition. *Nutr. Rev.* 2021. [CrossRef]

22. Hindy, G.; Sonestedt, E.; Ericson, U.; Jing, X.; Zhou, Y.; Hansson, O.; Renstrom, E.; Wirfalt, E.; Orho-Melander, M. Role of TCF7L2 risk variant and dietary fibre intake on incident type 2 diabetes. *Diabetologia* 2012, 55, 2646–2654. [CrossRef] [PubMed]

23. Cooper, A.J.; Forouhi, N.G.; Ye, Z.; Buissse, B.; Arriola, L.; Balkau, B.; Barricarte, A.; Beulens, J.W.; Boeing, H.; Buchner, F.L.; et al. Fruit and vegetable intake and type 2 diabetes: EPIC-InterAct prospective study and meta-analysis. *Eur. J. Clin. Nutr.* 2012, 66, 1082–1092. [CrossRef] [PubMed]

24. Helgason, A.; Palsson, S.; Thorleifsson, G.; Grant, S.F.; Emilsson, V.; Gunnarsdottir, S.; Adeyemo, A.; Chen, Y.; Chen, G.; Reynolds, T.; et al. Refining the impact of TCF7L2 genotype variants on type 2 diabetes and adaptive evolution. *Nat. Genet.* 2007, 39, 218–225. [CrossRef]

25. Corella, D.; Coltell, O.; Sorli, J.V.; Estruch, R.; Quiles, L.; Martinez-Gonzalez, M.A.; Salas-Salvado, J.; Castaner, O.; Aros, F.; Ortega-Calvo, M.; et al. Polymorphism of the Transcription Factor 7-Like 2 Gene (TCF7L2) Interacts with Obesity on Type-2 Diabetes in the PREDIMED Study Emphasizing the Heterogeneity of Genetic Variants in Type-2 Diabetes Risk Prediction: Time for Obesity-Specific Genetic Risk Scores. *Nutrients* 2016, 8, 793. [CrossRef]

26. Ouhaibi-Djellouli, H.; Mediene-Benchekor, S.; Lardjam-Hetraf, S.A.; Hamani-Medjaoui, I.; Meroufel, D.N.; Boulenouar, H.; Hermant, X.; Saidi-Mehtar, N.; Amouyel, P.; Houti, L.; et al. The TCF7L2 rs7903146 polymorphism, dietary intakes and type 2 diabetes risk in an Algerian population. *BMC Genet.* 2014, 15, 134. [CrossRef]

27. Dashti, H.S.; Folli, J.L.; Smith, C.E.; Tanaka, T.; Garaulet, M.; Gottlieb, D.J.; Hruby, A.; Jacques, P.F.; Kieft-de Jong, J.C.; Lamon-Fava, S.; et al. Gene-Environment Interactions of Circadian-Related Genes for Cardiometabolic Traits. *Diabetes Care* 2015, 38, 1456–1466. [CrossRef]

28. Kang, R.; Kim, S.; Chae, J.S.; Lee, S.H.; Lee, J.H. Consumption of whole grains and legumes modulates the genetic effect of the APOA5 -1131C variant on changes in triglyceride and apolipoprotein A-V concentrations in patients with impaired fasting glucose or newly diagnosed type 2 diabetes. *Trials* 2014, 15, 100. [CrossRef]

29. Dashti, H.S.; Smith, C.E.; Lee, Y.C.; Parnell, L.D.; Lai, C.Q.; Arnett, D.K.; Ordovas, J.M.; Garaulet, M. CRY1 circadian gene variant interacts with carbohydrate intake for insulin resistance in two independent populations: Mediterranean and North American. *Chronobiol. Int.* 2014, 31, 660–667. [CrossRef]

30. Huang, T.; Huang, J.; Qi, Q.; Li, Y.; Bray, G.A.; Rood, J.; Sacks, F.M.; Qi, L. PCSK7 genotype modifies effect of a weight-loss diet on 2-year changes of insulin resistance: The Pounds Lost trial. *Diabetes Care* 2015, 38, 439–444. [CrossRef]

31. Nettleton, J.A.; McKeown, N.M.; Kanoni, S.; Lemaitre, R.N.; Hivert, M.F.; Ngwa, J.; van Rooij, F.J.; Sonestedt, E.; Wojczynski, M.K.; Ye, Z.; et al. Polymorphism of the Transcription Factor 7-Like 2 Gene (TCF7L2) Interacts with Obesity on Type-2 Diabetes in the PREDIMED Study Emphasizing the Heterogeneity of Genetic Variants in Type-2 Diabetes Risk Prediction: Time for Obesity-Specific Genetic Risk Scores. *Nutrients* 2016, 8, 793. [CrossRef]

32. Xu, M.; Qi, Q.; Liang, J.; Bray, G.A.; Hu, F.B.; Sacks, F.M.; Qi, L. Genetic determinant for amino acid metabolites and changes in body weight and insulin resistance in response to weight-loss diets: The Preventing Overweight Using Novel Dietary Strategies (Pounds Lost) trial. *Circulation* 2013, 127, 1283–1289. [CrossRef] [PubMed]

33. Goni, L.; Qi, L.; Cuervo, M.; Milagro, F.I.; Saris, W.H.; MacDonald, I.A.; Langin, D.; Astrup, A.; Arner, P.; Oppert, J.M.; et al. Effect of the interaction between diet composition and the PPM1K genetic variant on insulin resistance and beta cell function markers during weight loss: Results from the Nutrient Gene Interactions in Human Obesity: Implications for dietary guidelines (Nugenob) randomized trial. *Am. J. Clin. Nutr.* 2017, 106, 902–908. [CrossRef] [PubMed]

34. Han, L.; Ma, W.; Sun, D.; Heianza, Y.; Wang, T.; Zheng, Y.; Huang, T.; Duan, D.; Bray, J.G.A.; Champagne, C.M.; et al. Genetic variation of habitual coffee consumption and glycemic changes in response to weight-loss diet intervention: The Preventing Overweight Using Novel Dietary Strategies (Pounds Lost) trial. *Am. J. Clin. Nutr.* 2017, 106, 1321–1326. [CrossRef]

35. Garaulet, M.; Lee, Y.C.; Shen, J.; Parnell, L.D.; Arnett, D.K.; Tsai, M.Y.; Lai, C.Q.; Ordovas, J.M. Clock genetic variation and metabolic syndrome risk: Modulation by monounsaturated fatty acids. *Am. J. Clin. Nutr.* 2009, 90, 1466–1475. [CrossRef]
36. Wang, T.; Huang, T.; Zheng, Y.; Rood, J.; Bray, G.A.; Sacks, F.M.; Qi, L. Genetic variation of fasting glucose and changes in glycemia in response to 2-year weight-loss diet intervention: The Pounds Lost trial. *Int. J. Obses.* 2016, 40, 1164–1169. [CrossRef]

37. Garcia-Rios, A.; Gomez-Delgado, F.J.; Garaulet, M.; Alcala-Diaz, J.F.; Delgado-Lista, F.J.; Marin, C.; Rangel-Zuniga, O.A.; Rodriguez-Cantalejo, F.; Gomez-Luna, P.; Ordovas, J.M.; et al. Beneficial effect of Clock gene polymorphism rs1801260 in combination with low-fat diet on insulin metabolism in the patients with metabolic syndrome. *Chronobiol. Int.* 2014, 31, 401–408. [CrossRef]

38. Ferguson, J.F.; Phillips, C.M.; Tierney, A.C.; Perez-Martinez, P.; Defoort, C.; Helal, O.; Lairo, D.; Planells, R.; Shaw, D.I.; Lovegrove, J.A.; et al. Gene-nutrient interactions in the metabolic syndrome: Single nucleotide polymorphisms in ADIPOQ and ADIPOR1 interact with plasma saturated fatty acids to modulate insulin resistance. *Am. J. Clin. Nutr.* 2010, 91, 794–801. [CrossRef]

39. Corella, D.; Asensio, E.M.; Coltell, O.; Sorli, J.V.; Estruch, R.; Martinez-Gonzalez, M.A.; Salas-Salvado, J.; Castaner, O.; Aros, F.; Lapetra, J.; et al. Clock gene variation is associated with incidence of type-2 diabetes and cardiovascular diseases in type-2 diabetic subjects: Dietary modulation in the PREIDIMED randomized trial. *Cardiovasc. Diabetol.* 2016, 15, 4. [CrossRef]

40. Phillips, C.M.; Goumidi, L.; Bertrais, S.; Field, M.R.; McManus, R.; Hercberg, S.; Lairon, D.; Planells, R.; Roche, H.M. Dietary saturated fat, gender and genetic variation at the TCF7L2 locus predict the development of metabolic syndrome. *J. Nutr. Biochem.* 2012, 23, 239–244. [CrossRef]

41. Phillips, C.M.; Goumidi, L.; Bertrais, S.; Field, M.R.; Ordovas, J.M.; Cupples, L.A.; Defoort, C.; Lovegrove, J.A.; Drevon, C.A.; Blaak, E.E.; et al. Leptin receptor polymorphisms interact with polyunsaturated fatty acids to augment risk of insulin resistance and metabolic syndrome in adults. *J. Nutr.* 2010, 140, 238–244. [CrossRef] [PubMed]

42. Huang, T.; Ley, S.H.; Zheng, Y.; Wang, T.; Bray, G.A.; Sacks, F.M.; Qi, L. Genetic susceptibility to diabetes and long-term improvement of insulin resistance and beta cell function during weight loss: The Preventing Overweight Using Novel Dietary Strategies (Pounds Lost) trial. *Am. J. Clin. Nutr.* 2016, 104, 198–204. [CrossRef] [PubMed]

43. Chen, Y.; Zhou, T.; Sun, D.; Li, X.; Ma, H.; Liang, Z.; Heianza, Y.; Pei, X.; Bray, G.A.; Sacks, F.M.; et al. Distinct genetic subtypes of adiposity and glycemic changes in response to weight-loss diet intervention: The Pounds Lost trial. *Eur. J. Nutr.* 2020, 1–10. [CrossRef] [PubMed]

44. Qi, Q.; Zheng, Y.; Huang, T.; Rood, J.; Bray, G.A.; Sacks, F.M.; Qi, L. Vitamin D metabolism-related genetic variants, dietary protein intake and improvement of insulin resistance in a 2 year weight-loss intervention study: Pounds Lost. *Diabetologia* 2015, 58, 2791–2799. [CrossRef] [PubMed]

45. Blanco-Rojo, R.; Delgado-Lista, J.; Lee, Y.C.; Lai, C.Q.; Perez-Martinez, P.; Rangel-Zuniga, O.; Smith, C.E.; Hidalgo, B.; Alcala-Diaz, J.F.; Gomez-Delgado, F.; et al. Interaction of an S100A9 gene variant with saturated fat and carbohydrates to modulate insulin resistance in 3 populations of different ancestries. *Am. J. Clin. Nutr.* 2016, 104, 508–517. [CrossRef]

46. Qi, Q.; Bray, G.A.; Hu, F.B.; Sacks, F.M.; Qi, L. Weight-loss diets modify glucose-dependent insulinotropic polypeptide receptor rs2287019 genotype effects on changes in body weight, fasting glucose, and insulin resistance: The Preventing Overweight Using Novel Dietary Strategies (Pounds Lost) trial. *Am. J. Clin. Nutr.* 2012, 95, 506–513. [CrossRef]

47. Qi, Q.; Bray, G.A.; Smith, S.R.; Hu, F.B.; Sacks, F.M.; Qi, L. Insulin receptor substrate 1 gene variation modifies insulin resistance response to weight-loss diets in a 2-year randomized trial: The Preventing Overweight Using Novel Dietary Strategies (Pounds Lost) trial. *Circulation* 2011, 124, 563–571. [CrossRef]

48. Corella, D.; Qi, L.; Tai, E.S.; Deurenberg-Yap, M.; Tan, C.E.; Chew, S.K.; Ordovas, J.M. Perilipin gene variation determines higher susceptibility to insulin resistance in Asian women when consuming a high-saturated fat, low-carbohydrate diet. *Diabetes Care* 2006, 29, 1313–1319. [CrossRef]

49. Qi, L.; Cornelis, M.C.; Zhang, C.; van Dam, R.M.; Hu, F.B. Genetic predisposition, Western dietary pattern, and the risk of type 2 diabetes in men. *Am. J. Clin. Nutr.* 2009, 89, 1453–1458. [CrossRef]

50. Utge, S.J.; Soronen, P.; Loukola, A.; Kronholm, E.; Ollila, H.M.; Pirkola, S.; Porkka-Heiskanen, T.; Partonen, T.; Paunio, T. Systematic analysis of circadian genes in a population-based sample reveals association of TIMELESS with depression and sleep disturbance. *PLoS ONE* 2010, 5, e9259. [CrossRef]

51. Bouatia-Naji, N.; Bonnefond, A.; Cavalcanti-Proenca, C.; Sparso, T.; Holmkvist, J.; Marchard, M.; Delplanque, J.; Lobbens, S.; Rocheleau, G.; Durand, E.; et al. A variant near MTNR1B is associated with increased fasting plasma glucose levels and type 2 diabetes risk. *Nat. Genet.* 2009, 41, 89–94. [CrossRef] [PubMed]

52. Garcia-Rios, A.; Gomez-Delgado, F.J.; Garaulet, M.; Alcala-Diaz, J.F.; Delgado-Lista, F.J.; Marin, C.; Rangel-Zuniga, O.A.; Rodriguez-Cantalejo, F.; Gomez-Luna, P.; Ordovas, J.M.; et al. Beneficial effect of Clock gene polymorphism rs1801260 in combination with low-fat diet on insulin metabolism in the patients with metabolic syndrome. *Chronobiol. Int.* 2014, 31, 401–408. [CrossRef]

53. Chambers, E.S.; Byrne, C.S.; Frost, G. Carbohydrate and human health: Is it all about quality? *Lancet* 2019, 393, 384–386. [CrossRef]

54. He, M.; van Dam, R.M.; Rimm, E.; Hu, F.B.; Qi, L. Whole-grain, cereal fiber, bran, and germ intake and the risks of all-cause and cardiovascular disease-specific mortality among women with type 2 diabetes mellitus. *Circulation* 2010, 121, 2162–2168. [CrossRef] [PubMed]

55. Lopez-Ortiz, M.M.; Garay-Sevilla, M.E.; Tejero, M.E.; Perez-Luque, E.L. Analysis of the interaction between transcription factor 7-like 2 genetic variants with nopal and wholegrain fibre intake: Effects on anthropometric and metabolic characteristics in type 2 diabetes patients. *Br. J. Nutr.* 2016, 116, 969–978. [CrossRef] [PubMed]
56. Sparso, T.; Andersen, G.; Nielsen, T.; Burgdorf, K.S.; Gjesing, A.P.; Nielsen, A.L.; Albrechtsen, A.; Rasmussen, S.S.; Jørgensen, T.; Borch-Johnsen, K.; et al. The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinemia, and reduced risk of type 2 diabetes. *Diabetologia* **2008**, *51*, 70–75. [CrossRef]

57. Ericson, U.; Helström, S.; Brunkwall, L.; Schulz, C.A.; Sønstedt, E.; Wallström, P.; Gullberg, B.; Wirfalt, E.; Otho-Melander, M. Food sources of fat may clarify the inconsistent role of dietary fat intake for incidence of type 2 diabetes. *Am. J. Clin. Nutr.* **2015**, *101*, 1065–1080. [CrossRef] [PubMed]

58. Salas-Salvador, J.; Bulló, M.; Estruch, R.; Ros, E.; Covas, M.I.; Ibarrola-Jurado, N.; Corella, D.; Aros, F.; Gomez-Gracia, E.; Ruiz-Gutierrez, V.; et al. Prevention of diabetes with Mediterranean diets: A subgroup analysis of a randomized trial. *Ann. Intern. Med.* **2014**, *160*, 1–10. [CrossRef]

59. Nicolopoulos, K.; Mulugeta, A.; Zhou, A.; Hypponen, E. Association between habitual coffee consumption and multiple disease outcomes: A Mendelian randomisation phenotype-wide association study in the UK Biobank. *Clin. Nutr.* **2020**, *39*, 3467–3476. [CrossRef]

60. Ding, M.; Bhupathiraju, S.N.; Chen, M.; van Dam, R.M.; Hu, F.B. Caffeinated and decaffeinated coffee consumption and risk of type 2 diabetes: A systematic review and a dose-response meta-analysis. *Diabetes Care* **2014**, *37*, 569–586. [CrossRef]

61. Siri-Tarino, P.W.; Chiu, S.; Bergeron, N.; Krauss, R.M. Saturated Fats versus Polyunsaturated Fats versus Carbohydrates for Cardiovascular Disease Prevention and Treatment. *Annu. Rev. Nutr.* **2015**, *35*, 517–543. [CrossRef] [PubMed]

62. De Souza, R.J.; Mente, A.; Maroleanu, A.; Cozma, A.I.; Ha, V.; Kishibe, T.; Uleryk, E.; Budyłowski, P.; Schunemann, H.; Beyene, J.; et al. Intake of saturated and trans unsaturated fatty acids and risk of all cause mortality, cardiovascular disease, and type 2 diabetes: Systematic review and meta-analysis of observational studies. *BMJ* **2015**, *351*, h3978. [CrossRef] [PubMed]

63. Luger, M.; Holstein, B.; Schindler, K.; Kruschitz, R.; Ludvik, B. Feasibility and efficacy of an isocaloric high-protein vs. standard diet on insulin requirement, body weight and metabolic parameters in patients with type 2 diabetes on insulin therapy. *Exp. Clin. Endocrinol. Diabetes* **2013**, *121*, 286–294. [CrossRef] [PubMed]

64. Dong, J.Y.; Zhang, Z.L.; Wang, P.Y.; Qin, L.Q. Effects of high-protein diets on body weight, glycaemic control, blood lipids and blood pressure in type 2 diabetes: Meta-analysis of randomised controlled trials. *Br. J. Nutr.* **2013**, *110*, 781–789. [CrossRef] [PubMed]

65. Thanopoulou, A.; Karamanos, B.; Angelico, F.; Assaad-Khalil, S.; Barbato, A.; Del Ben, M.; Djordjevic, P.; Dimitrijevic-Sreckovic, V.; Gallotti, C.; Katsilambros, N.; et al. Nutritional habits of subjects with Type 2 diabetes mellitus in the Mediterranean Basin: Comparison with the non-diabetic population and the dietary recommendations. Multi-Centre Study of the Mediterranean Group for the Study of Diabetes (MGSD). *Diabetologia* **2004**, *47*, 367–376. [CrossRef] [PubMed]

66. Mazzeoci, A.; Leone, L.; Agostoni, C.; Pali-Scholl, I. The Secrets of the Mediterranean Diet. Does [Only] Olive Oil Matter? *Nutrients* **2019**, *11*, 2941. [CrossRef]

67. Ditano-Vazquez, P.; Torres-Pena, J.D.; Galeano-Valle, F.; Perez-Caballero, A.I.; Demelo-Rodriguez, P.; Lopez-Miranda, J.; Katziki, N.; Delgado-Lista, J.; Alvarez-Sala-Walther, L.A. The Fluid Aspect of the Mediterranean Diet in the Prevention and Management of Cardiovascular Disease and Diabetes: The Role of Polyphenol Content in Moderate Consumption of Wine and Olive Oil. *Nutrients* **2019**, *11*, 2833. [CrossRef]

68. Matalas, A.L. Disparities within traditional Mediterranean food patterns: An historical approach of the Greek diet. *Int. J. Food Sci. Nutr.* **2006**, *57*, 529–536. [CrossRef]

69. Lopez-Minguez, J.; Saxena, R.; Bandin, C.; Scheer, F.A.; Garaulet, M. Late dinner impairs glucose tolerance in MTNR1B risk allele carriers: A randomized, cross-over study. *Clin. Nutr.* **2018**, *37*, 1133–1140. [CrossRef]

70. Karamitri, A.; Jockers, R. Melatonin in type 2 diabetes mellitus and obesity. *Nat. Rev. Endocrinol.* **2019**, *15*, 105–125. [CrossRef]

71. Lane, J.M.; Chang, A.M.; Bjorndal, A.C.; Aeschbach, D.; Anderson, C.; Cade, B.E.; Cain, S.W.; Czeisler, C.A.; Gharib, S.A.; Gooley, J.J.; et al. Impact of Common Diabetes Risk Variant in MTNR1B on Sleep, Circadian, and Melatonin Physiology. *Diabetes* **2016**, *65*, 1741–1751. [CrossRef] [PubMed]

72. Diamond, J. The double puzzle of diabetes. *Nature* **2003**, *423*, 599–602. [CrossRef] [PubMed]